natgillin/translations-raw huggingface dataset:
Genotypes Non-1: The decision to extend therapy to one year in patients with negative HCVRNA after six months of treatment should be based on other prognostic factors (e.g., age > 40 years, male gender, bridging fibrosis).
Genotipi ne-1: Odločitev o podaljšanju terapije na eno leto pri bolnikih z negativno vrednostjo serumske RNA-HCV po šestih mesecih zdravljenja mora temeljiti na drugih prognostičnih dejavnikih (npr. starost > 40 let, moški spol, premostitvena fibroza).
Genotypic analysis showed mutations in the HIV-1 RT gene Y181C and/or V106A depending upon the virus strain and cell line employed.
Genotipska analiza je pokazala mutacije genov Y181C in/ali V106A pri RT virusa HIV-1 , odvisno od virusnega seva in uporabljene celične linije.
Genotypic analysis showed mutations in the HIV-1 RT gene Y181C and/or V106A depending upon the virus strain and cell line employed.
Genotipska analiza je pokazala mutacje genov Y181C in/ali V106A pri RT virusa HIV-1 , odvisno od virusnega seva in uporabljene celične linije.
Genotypic analysis was conducted for 5 subjects in the tenofovir disoproxil fumarate arm post week 48.
Genotipsko analizo so opravili za 5 bolnikov v skupini z dizoproksiltenofovirijevim fumaratom po 48. tednu.
Genotypic Entecavir Resistance Through Year 5, Lamivudine-Refractory Studies
Genotipska odpornost proti entekavirju tekom 5 let v študijah pri bolnikih, neodzivnih na lamivudin
Genotypic evaluations performed on all patients with HBV DNA > 400 copies/ml at week 48 (n = 16), 96 (n = 5), 144 (n = 1), 192 (n = 2), 240 (n = 1), 288 (n = 1) and 384 (n = 2) of tenofovir disoproxil fumarate monotherapy showed that no mutations associated with tenofovir disoproxil fumarate resistance have developed.
Genotipska ocena, ki so jo opravili pri vseh bolnikih s HBV DNA > 400 kopij/ml v 48. (n = 16), 96. (n = 5), 144. (n = 1), 192. (n = 2), 240. (n = 1), 288. (n = 1) in 384. (n = 2) tednu, ko so prejemali monoterapijo z dizoproksiltenofovirijevim fumaratom, je pokazala, da se niso razvile nobene mutacije, ki bi bile povezane z rezistenco na dizoproksiltenofovirijev fumarat.
Genotypic or phenotypic testing (when available) and treatment history should guide the use of PREZISTA.
Izvidi genotipskega in fenotipskega testiranja (če so na voljo) ter zgodovina zdravljenja morajo biti vodilo pri uporabi zdravila PREZISTA.
Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the efavirenz + emtricitabine + tenofovir disoproxil fumarate group and in virus from 21/29 (72%) patients in the efavirenz + lamivudine/zidovudine group.
Genotipska rezistenca na efavirenz, pretežno mutacija K103N, se je pojavila pri virusih 13 od 19 (68 %) bolnikov v skupini, ki je prejemala efavirenz + emtricitabin + dizoproksiltenofovirijev fumarat, ter pri virusih 21 od 29 (34,5 %) bolnikov v skupini, ki je prejemala efavirenz + lamivudin/zidovudin.
Genotypic resistance: Key mutations (V3-loop) can presently not be suggested due to the high variability of the V3-sequence, and the low number of samples analysed.
Genotipska odpornost: Zaradi visoke variabilnosti zaporedja V3-zanke in majhnega števila analiziranih vzorcev trenutno ne moremo domnevati, da je prišlo do ključne mutacije V3-zanke.
Genotypic resistance: mutations were found to accumulate in the gp120 envelope glycoprotein (the viral protein that binds to the CCR5 co-receptor).
Genotipska odpornost: Ugotovljeno je bilo kopičenje mutacij v ovojničnem glikoproteinu gp120 (virusna beljakovina, ki se veže na soreceptor CCR5).
Genotypic Susceptibility Score* <2
Ocena genotipske občutljivosti* < 2
Genotypic Susceptibility Score* =2
Ocena genotipske občutljivosti * = 2
Genotypically Resistant
Genotipsko odporni
Gentamicin is known to be associated with ototoxicity when administered by the systemic route at higher doses.
Znana je povezava gentamicina z ototoksičnostjo, kadar se daje po sistemski poti v odmerku, večjem od terapevtskega..
Gentamicin sulfate
gentamicinijev sulfat
Gentamicin, at most.......................................................................................................................
Gentamicin, največ........................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamicin, največ...........................................................................................................................
Gentamicin, at most..........................................................................................................................
Gentamicin, največ.............................................................................................................................
Gently agitate the infusion bag containing the diluted Soliris solution to ensure thorough mixing of the medicinal product and diluent.
Infuzijsko vrečko z razredčenim zdravilom Soliris rahlo pretresite, da zagotovite temeljito mešanje zdravila in vehikla za redčenje.
Gently agitate to mix thoroughly.
Z rahlim stresanjem vsebino dobro premešajte.
Gently bend the patch and remove the first piece of protective liner, which covers the sticky surface of the patch.
Nežno upognite obliž in odstranite prvo plast zaščitne folije, ki pokriva lepljivo površino obliža.
Gently empty Aptivus oral solution from the syringe into your child’s mouth.
Narahlo izlijte peroralno raztopino zdravila Aptivus iz brizge v otrokova usta.
Gently flip the pink needle cover up, over the needle and snap into place, and set the syringe with needle on the work surface.
Previdno obrnite rožnati pokrovček igle gor, čez iglo, da se zaskoči na mesto, in položite brizgo z iglo na delovno površino.
Gently grasp the cleaned area of skin with one hand and hold firmly.
Z eno roko nežno primite očiščeni predel kože in ga čvrsto držite.
Gently grasp the cleaned skin at the injection site with one hand.
Nežno primite očiščeno kožo na vbodnem mestu z eno roko.
Gently hold the single-dose container with your thumb supporting it at the plunger at the bottom and your index and middle finger on either side of the spray tip (see drawing).
Nežno primite enoodmerni vsebnik tako, da s palcem podprete bat spodaj, kazalec in sredinec pa postavite na obe strani konice pršila (glejte risbo).
Gently insert the capsule into the chamber with the widest end first.
. Previdno vstavite kapsulo v komoro, s širšim delom naprej.
Gently invert or lightly massage the infusion bag to mix the diluted solution.
Nežno obrnite ali nalahko gnetite infuzijsko vrečko, da zmešate razredčeno raztopino.
Gently invert the bag 2-3 times (see ‘How to use IVEMEND’).
Vrečko 2 do 3 krat nežno obrnite (glejte "Kako uporabljati zdravilo IVEMEND").
Gently invert the bag/container to mix the solution.
Raztopino v vrečki/vsebniku premešajte z nežnim obračanjem.
Gently invert the container to mix.
Vsebnik nežno obračajte, da se vsebina ustrezno premeša.
Gently invert the container to mix.
Vsebnik nežno obrnite, da zagotovite zadostno mešanje.
Gently invert the TYSABRI solution to mix completely.
Raztopino zdravila TYSABRI nežno obračajte, da se povsem premeša.
Gently let go of the fold of skin.
Nežno izpustite kožno gubo.
Gently massage the injection site with a dry cotton ball or gauze.
Nežno masirajte mesto injiciranja s suhim kosom vate ali gazo.
Gently mix and re- suspend the contents of the bag, inspecting for clumps and clots.
Vsebino vrečke nežno premešajte in ponovno suspendirajte ter preverite, ali vsebuje grudice ali strdke.
Gently mix before use.
Pred uporabo vsebino rahlo premešajte.
Gently mix.
Nežno premešajte.
Gently move the dose preparation guide in circles a few times to dissolve the powder (see Diagram 8).
Nekajkrat nežno krožno zavrtite podstavek z vialo, da se prašek raztopi (glejte sliko 8).
Gently move the syringe and vial in a circle for at least 1 minute.
Brizgo in vialo nežno premikajte v krogu najmanj 1 minuto.
Gently move the syringe and vial upwards until they are the other way up.
Brizgo in vialo nežno obračajte navzgor, dokler ne bosta obrnjeni na glavo.
Gently pinch a fold of skin at the cleaned injection site.
Nežno uščipnite kožo, da na očiščenem mestu injiciranja ustvarite gubo.
Gently pinch the cleaned skin between your thumb and index finger.
Nežno stisnite očiščeno kožo s palcem in kazalcem.
Gently pinch the skin at the injection site and insert the needle.
Nežno stisnite kožo na mestu za injiciranje in zabodite iglo.
Gently pinch the skin at the site of injection.
Kožo na mestu injiciranja rahlo stisnite v gubo.
Gently pinch the skin together around the site (to lift it up a bit).
Nežno stisnite kožo okoli mesta (da jo malce dvignete).
Gently pinch up a fold of skin at the place you have chosen to give yourself the injection.
Nežno primite kožno gubo na mestu, ki ste ga izbrali za samoinjiciranje zdravila.
Gently pinch up the skin around where you are going to inject and hold this firmly with your other hand.
Kožo okoli mesta injiciranja nežno stisnite in jo čvrsto držite z drugo roko.
Gently Press
Previdno pritisnite
Gently press a small piece of gauze over the needle site and cover with a protective dressing.
Na mesto vboda previdno položite majhen košček gaze, ki ga prekrijte z zaščitno oblogo.
Gently press in the plunger as far as it will go.
Nežno pritisnite na bat in ga potisnite navzdol, dokler gre.
Gently press on the base of the bottle to release one drop of AZARGA at a time.
Nežno pritisnite na dno kapalnega vsebnika, da bo vsakokrat pritekla po ena kapljica zdravila AZARGA.
Gently press on the base of the bottle to release one drop of AZOPT at a time.
Z rahlim pritiskom na dno kapalnega vsebnika vsakokrat iztisnite po eno kapljico zdravila AZOPT.
Gently press on the base of the bottle to release one drop of EMADINE at a time.
Nežno pritisnite na dno kapalnega vsebnika, da vsakokrat iztisnete po eno kapljico zdravila EMADINE.
Gently press on the base of the bottle to release one drop of NEVANAC at a time.
Z rahlim pritiskom na dno kapalnega vsebnika vsakokrat iztisnite po eno kapljico zdravila NEVANAC.
Gently press on the base of the bottle to release one drop of OPATANOL at a time.
Z rahlim pritiskom na dno kapalnega vsebnika vsakič iztisnite po eno kapljico zdravila OPATANOL.
Gently press on the base of the bottle to release one drop of SIMBRINZA at a time.
Nežno pritisnite na dno kapalnega vsebnika, da bo vsakokrat pritekla po ena kapljica zdravila SIMBRINZA.
Gently pull back the plunger of the syringe.
Bat brizge nežno povlecite nazaj.
Gently pull back the plunger.
Previdno potegnite bat navzven.
Gently pull down the lower eyelid to form a pocket.
Nežno povlecite spodnjo veko navzdol, da nastane žepek.
Gently pull your penis away from your body to its full length and hold the stretch for 30 seconds.
Penis nežno povlecite stran od telesa do celotne dolžine in ga držite iztegnjenega 30 sekund.
Gently push the injection needle onto the pen as shown in Diagram E. (Notice that the rear portion of the injection needle will pierce through the rubber membrane that you disinfected previously).
Nežno potisnite injekcijsko iglo na peresnik, kot je prikazano na sliki E. (Zadnji del injekcijske igle mora predreti gumijasto opno, ki ste jo prej razkužili).
Gently push the plunger all the way down until air is injected into the vial.
Nežno potisnite bat navzdol, tako da boste v vialo iztisnili zrak.
Gently release the skin.
Nežno spustite kožo.
Gently remove the tablet (Figure 2).
Tableto previdno vzemite ven (slika 2).
Gently roll the pen 10 times.
Peresnik nežno 10- krat povaljajte med dlanmi
Gently roll the vial between your palms for about 15 seconds.
Nežno valjajte vialo med dlanmi približno 15 sekund.
Gently rotate the pre-filled pen back and forth a few times to mix the medicine.
Nežno zavrtite napolnjen peresnik nekajkrat naprej in nazaj, zato da zmešate zdravilo
Gently rotate the vial until all powder is dissolved.
Vialo nežno obračajte, dokler se ne raztopi ves prašek.
Gently rub the gel onto the treatment area.
Gel nežno vtrite v prizadeto mesto.
Gently screw the syringe onto the vial adapter.
Brizgo rahlo privijte na adapter za vialo.
Gently set the vial with vial adapter down on your clean work surface.
Previdno odložite vialo z nameščenim adapterjem na čisto delovno površino.
Gently shake the bag to mix the antigen suspension with the diluent.
Nežno pretresite vrečko, da zmešate suspenzijo antigena in vehikel.
Gently shake the multidose vial each time before withdrawing a dose (0.5 ml) of the vaccine into a syringe.
Pred vsakim odvzemom odmerka (0,5 ml) cepiva v brizgo previdno pretresitevečodmerno vialo.
Gently shake the single dose container prior to use
Pred uporabo nežno stresite enoodmerni vsebnik.
Gently shake the vial to dissolve the tablet.
Nežno stresite vialo, da se tableta raztopi.
Gently shake vial
Vialo nežno pretresite
Gently squeeze one drop of the medicine onto your eye.
Nežno vkapajte eno kapljico zdravila v oko.
Gently squeeze the bottle to release one drop of DuoTrav at a time (picture 3).
Nežno stisnite kapalni vsebnik, da vsakokrat priteče po ena kapljica zdravila DuoTrav (slika 3).
Gently squeeze the bottle to release one drop of IZBA at a time. (picture 3)
Nežno stisnite kapalni vsebnik, da vsakokrat priteče po ena kapljica zdravila IZBA (slika 3).
Gently squeeze the bottle to release one drop of TRAVATAN at a time. (picture 3)
Nežno stisnite kapalni vsebnik, da vsakokrat priteče po ena kapljica zdravila TRAVATAN (slika 3).
Gently squeeze the bottle to release one drop of Yellox.
Nežno stisnite plastenko, tako da sprostite eno kapljico zdravila Yellox.
Gently squeeze the container to release one drop into the pocket between the eyelid and eye (picture 3).
Z rahlim pritiskom na vsebnik iztisnite eno kapljico zdravila EMADINE v žepek med veko in očesom (slika 3).
Gently squeeze the sides of the bottle until one drop is released into your eye (picture 2).
Rahlo stisnite stranici kapalnega vsebnika, dokler ne iztisnete kapljice v oko (slika 2).
Gently squirt the correct dose into the second bowl.
Nežno iztisnite vsebino iz odmernika v drugo posodo.
Gently stir the contents into the soft food, creating a mixture of cysteamine granules and the soft food.
Na rahlo vmešajte vsebino v mehko hrano, tako da dobite mešanico zrn cisteamina in hrane.
Gently straighten your penis one time a day.
Penis nežno ravnajte enkrat na dan.
Gently stretch your penis 3 times a day.
Penis nežno raztezajte 3-krat na dan.
Gently swirl
Previdno obračajte vialo
Gently swirl the contents in the vial until all materials are dissolved; DO NOT SHAKE.
Vsebino viale s previdnimi krožnimi gibi mešajte, dokler se vsi delci ne raztopijo; NE TRESITE.
Gently swirl the liquid, sliding the vial in a circular motion on a flat surface.
Previdno zmešajte tekočino, tako da z vialo krožite po ravni površini.
Gently swirl the powder vial until the powder is completely dissolved.
Nežno obračajte vialo s praškom, da se prašek povsem raztopi.
Gently swirl the solution by rotating the vial to dissolve the lyophilised powder.
Z vrtenjem viale rahlo premešajte raztopino, da se bo liofiliziran prašek raztopil.
Gently swirl the vial until all the powder has dissolved.
Nežno sučite vialo, dokler ni prašek povsem raztopljen.
Gently swirl to facilitate complete dissolution of the powder.
Nežno vrtite vialo, da omogočite popolno raztapljanje praška.
Gently swirl.
Previdno vrtite.
Gently swirl.
Rahlo vrtite.
Gently tap the syringe barrel with your fingers until the air bubble/gap rises to the top of the syringe.
S prsti rahlo potrkajte po valju brizge, da se zračni mehurček/prazni prostor dvigne na vrh brizge.
Gently tap the syringe so the large air bubbles rise to the top.
Rahlo potrkajte po brizgi, tako da se bodo večji zračni mehurčki dvignili proti vrhu.
Gently tap the syringe to make any bubbles rise to the top of the syringe, near the needle (see Diagram 10).
Rahlo potrkajte po brizgi, da se bodo mehurčki dvignili na vrh brizge, v bližino igle (glejte sliko 10).
Gently tap the syringe until air bubbles rise to the top of the syringe (see Figure 5).
Nalahno potrkajte po brizgi, da se zračni mehurčki dvignejo na vrh brizge (glejte sliko 5).
Gently tap to bring air bubbles to the top.
Na rahlo trkajte po injekcijski brizgi, da spravite zračne mehurčke na vrh.
Gently turn the dose setting knob clockwise.
Nežno sukajte gumb za nastavitev odmerka v smeri urinega kazalca.
Gently turn the vial upside down.
Počasi obrnite vialo z zgornjo stranjo navzdol.
Gently wash the area with soap and water to remove it.
Odstranite jo, tako da jo previdno umijete z milom in vodo.
Gently, turn the needle clockwise until it is firmly attached, otherwise the needle may leak.
Nežno obrnite iglo v desno, dokler ni čvrsto pritrjena, sicer lahko pušča.
Genuair inhaler there are 2 steps patients need to perform after removing the cap.
Inhalator Genuair se uporablja v 2 korakih, ki ju morajo bolniki izvesti po odstranitvi pokrovčka.
Genvoya (n = 866)
Zdravilo Genvoya (n = 866)
Genvoya (n = 959)
Zdravilo Genvoya (n = 959)
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets
Genvoya 150 mg/150 mg/200 mg/10 mg filmsko obložene tablete elvitegravir/kobicistat/emtricitabin/alafenamidtenofovirat
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Genvoya 150 mg/150 mg/200 mg/10 mg filmsko obložene tablete elvitegravir/kobicistat/emtricitabin/alafenamidtenofovirat
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets.
Genvoya 150 mg/150 mg/200 mg/10 mg filmsko obložene tablete
Genvoya [Outer packaging only]
Genvoya [samo na zunanji ovojnini]
Genvoya contains four active substances:
Zdravilo Genvoya vsebuje štiri zdravilne učinkovine:
Genvoya is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
Zdravilo Genvoya je ena sama tableta za zdravljenje okužbe z virusom človeške imunske pomanjkljivosti 1 (HIV-1) pri odraslih in mladostnikih, starih 12 let in več, s telesno maso vsaj 35 kg.
Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir (see sections 4.2 and 5.1).
Zdravilo Genvoya je indicirano za zdravljenje odraslih in mladostnikov (starih 12 let in več s telesno maso vsaj 35 kg), okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1) brez kakršnih koli znanih mutacij, povezanih z rezistenco proti skupini zaviralcev integraze, emtricitabinu ali tenofovirju (glejte poglavji 4.2 in 5.1).
Genvoya met the non-inferiority criteria in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF.
Zdravilo Genvoya je izpolnilo kriterije enakovrednosti pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z E/C/F/TDF.
Genvoya reduces the amount of HIV in your body.
Zdravilo Genvoya zmanjša količino virusa HIV v vašem telesu.
Genvoya should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Zdravljenje z zdravilom Genvoya je treba prekiniti pri bolnikih z ocenjenim CrCl, ki med zdravljenjem pade pod 30 ml/min (glejte poglavji 5.1 in 5.2).
Genvoya should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Zdravilo Genvoya se sme med nosečnostjo uporabljati samo, če možne koristi upravičujejo možno tveganje za plod.
Genvoya should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Zdravila Genvoya se ne sme dajati skupaj z zdravili, ki vsebujejo dizoproksiltenofovirat (v obliki fumarata), lamivudin ali dipivoksiladefovirat in se uporabljajo za zdravljenje okužbe s HBV.
Genvoya should not be administered concomitantly with medicinal products containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil used for the treatment of HBV infection.
Zdravila Genvoya se ne sme dajati skupaj z zdravili, ki vsebujejo dizoproksiltenofovirat (v obliki fumarata), lamivudin ali dipivoksiladefovirat, ki se uporabljajo za zdravljenje okužbe s HBV.
Genvoya should not be co-administered with colchicine to patients with renal or hepatic impairment.
Bolnikom z jetrno okvaro se zdravila Genvoya ne sme dajati sočasno s kolhicinom.
Genvoya should not be co-administered with other antiretroviral medicinal products.
Zdravila Genvoya se ne sme dajati sočasno z drugimi protiretrovirusnimi zdravili.
Genvoya should not be initiated in patients with estimated CrCl < 30 mL/min as there are limited data available regarding the use of Genvoya in this population (see sections 5.1 and 5.2).
Zdravila Genvoya se ne sme uvesti pri bolnikih z ocenjenim CrCl < 30 ml/min, saj so podatki glede uporabe zdravila Genvoya pri tej populaciji omejeni (glejte poglavji 5.1 in 5.2).
Genvoya was investigated in two main studies involving 1,733 adults infected with HIV-1 who had not been treated previously.
Zdravilo Genvoya so proučevali v dveh glavnih študijah s 1 733 odraslimi, okuženimi z virusom HIV-1, ki še niso bili zdravljeni.
Genvoya’s side effects were similar to those of the individual medicines.
Neželeni učinki zdravila Genvoya so bili podobni tistim, ki so značilni za posamezna zdravila.
Genzyme Europe B.V.
Genzyme Europe B. V.
Genzyme Europe B.V. - NL Store in a refrigerator.
Genzyme Europe B.V. - NL Shranjujte v hladilniku.
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, The Netherlands
Genzyme Europe B. V., Gooimeer 10, 1411 DD Naarden, Nizozemska
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, the Netherlands
Genzyme Europe B.V., Gooimeer 10, 1411 DD Naarden, Nizozemska.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, Nizozemska.
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD Naarden, The Netherlands
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, Nizozemska
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland.
Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska.
Genzyme Limited 37 Hollands Road Haverhill
37 Hollands Road Haverhill‌
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland‌
Genzyme Ltd., 37 Hollands Road – Haverhill, Suffolk CB9 8PU, Velika Britanija Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Irska
Geometric mean
Ctrough, vrednosti pred
Geometric mean (%CV†)
Geometrijska sredina (% KV†)
Geometric mean change (%)
Geometrična povprečna sprememba (%)
Geometric mean change (%)
Interakcija Geometrijsko povprečje spremembe (%)
Geometric Mean Change (%) in
Geometrična srednja sprememba (%) AUC,
Geometric mean changes (%)
Interakcija sprememba geometrične srednje vrednosti (%)
Geometric mean Ctrough and geometric mean AUCτ from the BP22333 and BO22334 trials are summarized in Table 8.
Geometrična sredina Ctrough in geometrična sredina površine pod krivuljo AUCτ v preskušanjih BP22333 in BO22334 sta povzeti v preglednici 8.
Geometric mean of titre (1/dil)
Geometrično povprečje titra (1/razr)
Geometric mean of titre ratio (GMTR)
Razmerje geometričnega povprečja titra (GMTR)
Geometric Mean Ratio (Ratio with/without peginterferon alfa-2b)
Razmerje geometričnih sredin (razmerje z/brez peginterferona alfa-2b)
Geometric Mean Titer
Geometrični povprečni titer
Geometric mean titer (by plaque reduction neutralization test)
Geometrična sredina titra (po testu Plaque Reduction Neutralization Test)
Geometric Mean Titer (plaque reduction neutralization test) GMT [95%CI]
Geometrični povprečni titer (nevtralizacijski test redukcije plakov) GMT [95 % IZ]